Product Catalogue 2026

External Quality Assessment

LABQUALITY

Product Catalogue 2026

Service information

Labquality EQAS
Labquality EQAS is provided by an independent Finnish external quality assessment provider with over 50 years of experience in helping clinical laboratories and POCT sites develop and maintain their performance. Labquality EQAS schemes are internationally recognised high-quality programs. The EQA programs have a clinical scope with an educational touch. Part of the EQA production is outsourced to expert laboratories and national partners.

Integrated EQA service (EQA3)
We are the first EQA provider to integrate pre-analytical, analytical, and post-analytical phases into its EQA programs. Advanced and traditional EQA schemes have been designed to fully support the total quality management system of the participating laboratories and fulfil ISO 15189 requirements concerning the extra-analytical phases. In addition to the samples, the integrated schemes include pre- and/or post-analytical questionnaires concerning the scope of the scheme.

Quality management
Our management system is certified according to ISO 9001 (sbcert), and the main EQA schemes are accredited according to ISO 17043 (FINAS, PT02, ISO 17043). The scope of accreditation is available on the FINAS website and the accreditation status of the EQA schemes is available on our website in the product search. The list of accredited schemes will be provided upon request.

EQA service availability
We have customers in over 60 countries in Europe, Asia, America and North Africa. The service is localised by 40 national partners. All digital schemes, including pre-analytical and diagnostic schemes for anatomic pathology, are available globally. With only a few exceptions, all schemes are globally available through national partners. For direct customers, the program selection is limited to the schemes with stable and non-hazardous sample materials.

Enrolment and prices
We offer annual programmes and pricing. Participants shall place their orders for the following year before the end of November to ensure participation in all needed EQA rounds. Enrolment is possible during the calendar year, but only part of the EQA rounds may be available. To place an order, please contact our national partner in your country or our customer service at **info@labquality.com**.

Distributions
Our specimen logistics system is accepted and continuously audited as part of accreditation according to the ISO 17043 (PT02/FINAS) standard. Specimens are shipped according to the annual schedule. We retain the right to make changes to the schedule.

LabScala EQA portal
Partners and participants can handle the whole EQA process, from orders to reports, through a modern web-based software, LabScala. The EQA process is designed to complement the laboratory process, from pre-analytics to post-analytics. Easy availability and a user-friendly interface guarantee an advanced experience.

Certificate
A certificate of participation will be provided upon request at the end of the calendar year. The certificate refers to EQA reports to evaluate the performance of the participant.

Customer service
Please contact our international partners (listed on our website: www.labquality.com) or customer service: **info@labquality.com**.

How to use the catalogue



Results processed: The number shows how many results from different analysers or tests within the same laboratory are allowed depending on scheme, when the sample volume is sufficient.

Updates for 2026

New schemes and products

2708	Human Erythropoietin and Thrombopoietin
2709	Phosphatidyl ethanol in blood (PEth)
2755	Biochemical indicators of vitamin B12 deficiency (HoloTC, MMA, Homocysteine)
2756	Immunosuppressants
5043	Gram stain, vaginal fluid
5241	*Bordetella pertussis/parapertussis*, nucleic acid detection
5305	Bacterial vaginosis and vaginitis multiplex, nucleic acid detection
5688	West Nile virus, antibodies
5689	HCV RNA from capillary blood, POCT
6800	HPV-related head and neck cancer control

Changes in distribution schedule

2510-2511, 2516-2517	Alcohol determinations (4 rounds/year)
2754	Faecal elastase (4 rounds/year)
2280	Procalcitonin (4 rounds/year)
3170	Urine bacterial screening with automated analysers (4 rounds/year)

Discontinued schemes and products

4156	Reticulocyte count, Mindray
4190	White blood cell differential count: HemoCue, POCT
4231	Leucocyte differential count, 5-part, automated: Cell-Dyn
4239	Leucocyte differential count, 5-part, automated: Mythic
5470	Parasites in blood, Giemsa stain, virtual microscopy
5471	Parasites in blood, MGG stain, virtual microscopy
5593	*Streptococcus pyogenes* (Group A), nucleic acid detection in pharyngeal sample
5636	Zika virus, antibodies
5677	SARS-CoV-2, antibodies

Changes in scope, specimens or parameters

5191	Faecal bacterial pathogens multiplex, nucleic acid detection. Examinations: *Clostridioides difficile* added.
5254	*Mycoplasma genitalium*, drug resistance, nucleic acid detection. Examinations: A fluoroquinolone (moxifloxacin) resistant sample will be included in some rounds.
5473	*Trichomonas vaginalis*, detection. Specimens: 2 simulated samples.
5595	*Streptococcus pyogenes* (Group A), detection in pharyngeal sample. Examinations: Strep A NAT added.
5620	*Chlamydia pneumoniae*, antibodies. Specimens: 2 samples/round.

2026 Planned pilot schemes

Pilot studies are EQA schemes under development. Information about pilot studies and schedules are updated on our website: **www.labquality.com/eqas/new-schemes/**

Clinical chemistry

The clinical chemistry portfolio covers areas of allergology, basic chemistry, cardiac markers, diabetes analysis, endocrinology, special chemistry, specific proteins, tumour markers and urine analysis. For routine chemistry needs, schemes with both one and two level samples enabling assessment of more than 50 analytes are available. A wide selection of schemes specifically tailored for POCT devices are also available, including e.g. those for drug abuse screening, glucose meters and troponin detection.

Clinical chemistry » Allergology

2675 Allergen component (UK NEQAS)

1	2	3	4	5	6	7	8	9	10	11	12
1	•		•		•		•		•	•	

Specimens: 2 liquid human serum samples for allergen component tests.

Examinations: Allergen component test which covers recombinant allergens as well as the ISAC system.

Notes: Organised in co-operation with UK NEQAS. Participation in all rounds is required. Register orders before the end of October. Limited availability.

2681 Allergy in vitro diagnostics (SKML)

1	2	3	4	5	6	7	8	9	10	11	12
1	•			•			•		•		

Specimens: 3 liquid human serum samples for specific IgEs with 3 allergens, 2 mixes and total IgE in each and some allergen components, 0.5 mL.

Examinations: Total IgE, specific IgEs, allergen mixes and allergen components.

Notes: Organised in co-operation with SKML. Participation in all rounds is required. Register orders before the end of October. All samples are distributed in February.

2670 Allergy in vitro diagnostics (UK NEQAS & Labquality)

1	2	3	4	5	6	7	8	9	10	11	12
1	•		•		•		•		•	•	

Specimens: 2 liquid human serum samples for specific IgEs with 4 allergens in each specimen, 0.5 mL each and 1 serum specimen for total IgE, 0.5 mL.

Examinations: Total IgE and specific IgEs.

Notes: Organised in cooperation with UK NEQAS. Participation in all rounds is required. Register orders before the end of October. Limited availability.

2680 Eosinophil cationic protein

1	2	3	4	5	6	7	8	9	10	11	12
1	•		•		•		•		•	•	

Specimens: 1 lyophilised human serum sample, 0.3 mL.

Examinations: ECP.

Notes: Results are processed in connection with total IgE results of scheme 2670.

2685 Tryptase (UK NEQAS)

1	2	3	4	5	6	7	8	9	10	11	12
1	•		•	•		•		•		•	

Specimens: 2 liquid human serum samples.

Examinations: Tryptase.

Notes: Organised in co-operation with UK NEQAS. Participation in all rounds is required. Register orders before the end of October. Limited availability.

Clinical chemistry » Basic chemistry

POCT

2100 Basic chemistry, POCT analysers

1	2	3	4	5	6	7	8	9	10	11	12
3	•			•			•			•	

Specimens: 2 human serum samples, 1 mL.

Examinations: Alanine aminotransferase, albumin, alkaline phosphatase, amylase (total and pancreatic), aspartate aminotransferase, calcium, chloride, HDL cholesterol, cholesterol, creatinekinase, creatinine, gamma glutamyltransferase, glucose, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, total protein, triglycerides, urea, uric acid.

Notes: For clinical laboratories and POCT sites. Only for dry chemistry analysers. If you are not sure whether your device is a POCT meter or an analyser, please contact our customer service.

2730 Erythrocyte sedimentation rate

1	2	3	4	5	6	7	8	9	10	11	12
3		•		•				•		•	

Specimens: 1 artificial blood cell suspension, ~ 4 mL.

Examinations: ESR.

Notes: Not suitable for Algor iSed and Mindray.

2731 Erythrocyte sedimentation rate: Alifax-analyser; Greiner tube

3

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 3 test tubes containing synthetic latex solution, 3 mL.
Examinations: ESR.

Notes: Only for Alifax analysers.

2732 Erythrocyte sedimentation rate: Alifax-analyser; Sarstedt tube

3

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 3 test tubes containing synthetic latex solution, 3 mL.
Examinations: ESR.

Notes: Only for Alifax analysers.

2750 Faecal occult blood, qualitative

3

1	2	3	4	5	6	7	8	9	10	11	12
•				•				•		•	

POCT

Specimens: 2 preparations that include human haemoglobin, 0.5 mL.
Examinations: Qualitative detection of Hb in human faeces.

Notes: For clinical laboratories and POCT sites.

2749 Faecal occult blood, quantitative

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

POCT

Specimens: 2 liquid samples (March, Sept) and 2 artificial stool samples (June, Dec) including human haemoglobin.
Examinations: Quantitative determination of Hb in human faeces (iFOB/FIT).

Notes: The liquid samples assess the analytical process only. The artificial stool samples asses both the preanalytical and analytical processes. One test-specific sample collection kit (not provided) per EQA sample is needed for artificial stool samples. For clinical laboratories and POCT sites.

2115 Haemoglobin, 1-level Hemocue 801 and HemoCue 301

3

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

POCT
EQA³

Specimens: 1 bovine sample, 1 mL.
Examinations: Haemoglobin, pre-analytical case yearly, timing not specified.

Notes: Only for HemoCue 801 and HemoCue 301.

2114 Haemoglobin, 1-level POC analysers

3

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

POCT
EQA³

Specimens: 1 bovine sample, 1 mL.
Examinations: Haemoglobin, pre-analytical case yearly, timing not specified.

Notes: Only for POCT devices. Not suitable for Diaspect, CompoLab, Hemocue 301 or Hemocue 801.

2113 Haemoglobin, 3-level samples, cell counters and analysers

3

1	2	3	4	5	6	7	8	9	10	11	12
								•			

Specimens: 3 human whole blood control samples, 1 mL (low, medium and high concentration).

Examinations: Haemoglobin linearity with three samples. Reference values will be provided in the summary report.
Notes: For cell counters and analysers.

2112 Haemoglobin, 3-level samples, POCT

3

1	2	3	4	5	6	7	8	9	10	11	12
								•			

POCT

Specimens: 3 bovine or human samples, 1 mL (low, medium and high concentration).
Examinations: Haemoglobin linearity with three samples.

Notes: Only for POCT devices. Not suitable for Diaspect, CompoLab, Hemocue 301 or Hemocue 801.

Clinical chemistry » Cardiac markers

1541 CRP, low concentration

3

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•			•		•	

Specimens: 1 Human serum sample, 1 mL.
Examinations: CRP.

Notes: CRP, low concentration sample is included in product 2541 Myocardiac markers and CRP.

2540 Myocardial markers (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•			•		•	

Specimens: 2 Human serum samples, 1 mL.
Examinations: CK-MB mass, myoglobin, quantitative troponin I, quantitative troponin T. Not for CKMB activity!

Notes: Suits clinical laboratory analysers. See also scheme 2530 Troponin I and T, detection for POCT. If you are not sure whether your device is a POCT meter or an analyser, please contact our customer service.

2541 Myocardial markers and CRP, low concentration (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•			•		•	

Specimens: 2 Human serum samples for myocardial markers, 1 mL and one for CRP, 1 mL.
Examinations: CK-MB mass, myoglobin, quantitative troponin I, quantitative troponin T and CRP, low concentration. Not for CKMB activity!

Notes: Suits clinical laboratory analysers. See also scheme 2530 Troponin I and T, detection for POCT. If you are not sure whether your device is a POCT meter or an analyser, please contact our customer service.

POCT

2690 Natriuretic peptides 1, B-type, NT-ProBNP (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 liquid samples, 3 mL.
Examinations: NT-ProBNP.

Notes: Suits both clinical laboratories and POCT sites. Also suitable for Roche Cardiac Reader and cobas h232.

POCT

2691 Natriuretic peptides 2, B-type, BNP (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 liquid samples, 3 mL.
Examinations: BNP.

Notes: For clinical laboratories and POCT sites.

POCT

2530 Troponin I and troponin T, detection, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•			•		•	

Specimens: 2 fresh human serum samples or 2 liquid human samples, 1 ml.
Examinations: Detection of troponin I and troponin T.

Notes: Qualitative and quantitative results are processed. This scheme is only for POCT, scheme 2540 is for analysers. If you are not sure whether your device is a POCT meter or an analyser, please contact our customer service.

Clinical chemistry » Diabetes analysis

POCT
EQA³

2570, 2580, 2590 Glucose meters, POCT (5)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•		•	

Device-specific product codes:
2570 for all glucose meters except Contour, HemoCue and On Call Plus
2580 for HemoCue meters
2590 for Contour meters

Specimens: 1 whole blood, plasma or serum sample of human origin or animal-based plasma sample, 1 mL
Examinations: Glucose, pre-analytical case yearly, timing not specified.
Notes: 5 results processed with one order if sample volume is sufficient and devices belong to the same product group.

1261 Haemoglobin A1c, liquid samples (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•		•		•		•

Specimens: 2 liquid blood samples, 0.5 mL.
Examinations: HbA1c.

Notes: The product is for laboratory analysers. 1263 is for POCT instruments. If you are not sure if your instrument is POCT or not, please contact our customer service. Not suitable for Afinion instruments.

POCT

1263 Haemoglobin A1c, liquid samples, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•		•				•		•

Specimens: 2 liquid blood samples, 0.5 mL.
Examinations: HbA1c.

Notes: Only for POCT devices. Not suitable for Afinion instruments.

POCT

2526 Ketones (beta-hydroxybutyrate) (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•							•		

Specimens: 2 serum samples, 0.4 mL.
Examinations: Beta-hydroxybutyrate.

Notes: For POCT sites and clinical laboratories. 3 results processed with one order if sample volume is sufficient.

Clinical chemistry » Endocrinology

2300, 2300S Hormones A: Basic analytes of hormone and immunochemistry

3

1	2	3	4	5	6	7	8	9	10	11	12
	•		•	•	•		•		•	•	•

EQA³

Specimens: 2 human serum samples with differing concentrations, 3 mL each. Liquid serum sample (one level) included in Apr and Oct rounds. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Ferritin, folate, hCG (total, intact), T3, free T3, T4, free T4, TSH, vitamin B12, active vitamin B-12, pre- and/or post-analytical indicators.

Notes: 2300S is a limited version of the scheme available for laboratories performing testing of 1–5 analytes. For additional set of samples, order scheme 1300. Product 2300S does not include reporting from multiple analysers or methods.

1300 Hormones A, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
	•		•	•	•		•		•	•	•

Specimens: 2 human serum samples, 3 mL.

Notes: Only in connection with scheme 2300.

2301, 2301S Hormones B: Steroid and peptide hormones

3

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•		•		•		•

EQA³

Specimens: 2 human serum samples with differing concentrations, 3 mL. Liquid serum sample (one level) included in Apr, Aug and Dec rounds. Pre- and/or postanalytical cases in part of the rounds.

Examinations: Androstenedione, aldosterone, C-peptide, cortisol, DHEAS, estradiol, FSH, gastrin, growth hormone, IGF-1, insulin, LH, progesterone, 17-OH-progesterone, prolactin, SHBG, testosterone, free testosterone, TBG, pre- and/or post-analytical indicators.

Notes: Reference values for 1 analyte in liquid serum will be provided. 2301S is a limited version of the scheme available for laboratories performing testing of 1–5 analytes. For additional set of samples, order scheme 1301. Product 2301S does not include reporting from multiple analysers or methods.

1301 Hormones B, extra set of samples

3

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•		•		•		•

Specimens: 2 human serum samples, 3 mL.

Notes: Only in connection with scheme 2301.

2250 Parathyroid hormone

3

1	2	3	4	5	6	7	8	9	10	11	12
		•							•		

EQA³

Specimens: 2 lyophilised human serum samples, 3 mL.

Examinations: PTH, intact.

2704 ACTH and cortisol

3

1	2	3	4	5	6	7	8	9	10	11	12
					•					•	

Specimens: 2 lyophilised human serum samples, 3 mL.

Examinations: Adrenocorticotropic hormone (ACTH) and Cortisol.

2706 Salivary Cortisol

3

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 2 liquid or lyophilised simulated salivary samples.

Examinations: Salivary cortisol.

2708 Human Erythropoietin and Thrombopoietin

3

1	2	3	4	5	6	7	8	9	10	11	12
			•					•			

NEW

Specimens: 2 lyophilised human serum samples, 1 mL.

Examinations: Erythropoietin and thrombopoietin.

2756 Immunosuppressants

3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

NEW

Specimens: 2 lyophilised human whole blood samples, 2 mL.

Examinations: Ciclosporin, tacrolimus, sirolimus, everolimus.

Clinical chemistry » General clinical chemistry, known concentration

1031 DayTrol, human serum

1	2	3	4	5	6	7	8	9	10	11	12
1	●	●	●	●	●	●	●	●	●	●	●	●

Specimens: 1 lyophilised human serum sample, 5 mL.

Examinations: Alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, calcium, chloride, cholesterol, cholesterol HDL, creatine phosphokinase, creatinine, gamma-glutamyltransferase, glucose, iron, lactate, lactate dehydrogenase, lithium, magnesium, osmolality, phosphorus, potassium, protein, sodium, thyreotropin, thyroxine, thyroxine free, transferrin, transferrin receptor, triglycerides, urea, uric acid.

Notes: The same sample is analysed on a daily or a weekly basis. Monthly averages and CV%s are compared with other participants. Minimum order quantity of 10 bottles per year. Monthly reporting is included.

Clinical chemistry » General clinical chemistry, unknown concentration

1072, 1072S General clinical chemistry, 1-level sample (Serum A)

1	2	3	4	5	6	7	8	9	10	11	12
3	●	●	●	●	●	●	●	●	●	●	●	●

Specimens: Lyophilised serum sample, 3 - 5 mL, samples are selected to cover a wide concentration range.

Examinations: Alanine aminotransferase, albumin, alkaline phosphatase, alpha-1-antitrypsin, alpha-1-glykoprotein, amylase, amylase (pancreatic), aspartate aminotransferase, bilirubin, calcium, calcium (ionized, actual), calcium (ionized, pH 7.4), chloride, cholesterol, cholesterol HDL, cholesterol LDL, cortisol, creatine phosphokinase, creatinine, ferritin, gamma-glutamyltransferase, glucose, haptoglobin, IgA, IgE, IgG, IgM, iron, lactate, lactate dehydrogenase, lithium, magnesium, oroso-mucoid, osmolality, phosphorus, potassium, protein, selenium, sodium, thyreotropin, thyroxine, thyroxine free, TIBC, transferrin, transferrin receptor, triglycerides, urea, uric acid.

Notes: Samples for multiple rounds shipped simultaneously. Monthly processing of results included. 1072S is a limited version of the scheme available for laboratories performing testing of 1–5 analytes. Product 1072S does not include reporting from multiple analysers or methods.

EQA[3]

2050 General clinical chemistry, 2-level sera (serum B and C)

1	2	3	4	5	6	7	8	9	10	11	12
3		●		●		●		●		●	●	

Specimens: 2 liquid human serum samples covering a wide concentration range, 3–5 mL.

Examinations: Alanine aminotransferase, albumin, alfa-1-antitrypcine, alfa-1-glycoprotein, alkaline phosphatase, amylase, pancreas amylase, aspartate aminotransferase, bilirubin, ferritin, phosphate, glucose, glutamyltransferase, haptoglobin, IgA, IgE, IgG, IgM, potassium, calcium, ionized calcium, ionized calcium pH corrected (7.4), chloride, cholesterol, HDL cholesterol, LDL cholesterol, cortisol, creatine kinase, creatinine, copper, lactate, lactate dehydrogenase, lipase, lithium, magnesium, sodium, osmolality, protein, iron binding capacity, iron, selenium, zinc, transferrin, transferrin receptor, triglycerides, tri-iodio-thyronine, thyrotropin, tyroxine, free tyroxine, urea, uric acid.

Notes: Comparison of two different concentration ranges simultaneously. Reference method values available occasionally for some of the analytes.

Clinical chemistry » Special chemistry

EQA[3]
POCT

2610 Acid-base status and electrolytes

1	2	3	4	5	6	7	8	9	10	11	12
1		●		●				●		●		

Specimens: 3 buffered artificial samples, 2.5 mL.

Examinations: Chloride, creatinine, glucose, ionized calcium, lactate, pCO2, pH, pO2, potassium, sodium, urea, base excess, HCO3.

Notes: Order one sample set for each analyser. For clinical laboratories and POCT sites.

2510 Alcohol in blood: Ethanol + methanol + isopropanol

1	2	3	4	5	6	7	8	9	10	11	12
3			●		●				●		●	

Specimens: Ethanol: 2-level whole blood samples. Methanol and isopropanol: 1-level whole blood samples.

Examinations: Ethanol, methanol, isopropanol.

2516 Alcohol in blood: Ethylene glycol in whole blood (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 1-level whole blood samples.

Examinations: Ethylene glycol.

2511 Alcohol in serum: Ethanol + methanol + isopropanol + acetone in serum (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: Ethanol: 2-level serum samples. Methanol, isopropanol and acetone: 1-level serum samples.

Examinations: Ethanol, methanol, isopropanol, acetone.

2517 Alcohol in blood: Ethylene glycol in serum (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 1-level serum samples.

Examinations: Ethylene glycol.

2105 Ammonium ion (1)

1	2	3	4	5	6	7	8	9	10	11	12
			•				•				•

Specimens: 2 serum based or buffered samples.

Examinations: Ammonium ion.

2210 Angiotensin convertase (ACE) (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•							

Specimens: 1 liquid and 1 lyophilised human serum sample, 1 mL.

Examinations: ACE.

2520 Bile acids (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•								•	

Specimens: 2 pooled human serum samples, 0.5 mL.

Examinations: Bile acids.

2109 Bilirubin, conjugated (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•				•		•		

Specimens: 2 lyophilised or liquid samples.

Examinations: Total bilirubin, conjugated bilirubin.

2040 Bilirubin, neonatal (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•		•		•		•

Specimens: 2 lyophilised or liquid samples.

Examinations: Bilirubin, neonatal.

8805 Cystatin C (DEKS) (5)

1	2	3	4	5	6	7	8	9	10	11	12
Two rounds per year.											

Specimens: 2 human plasma samples with reference target values, 0.75 mL.

Examinations: P-Cystatin C, P-Creatinine, P-eGFR.

Notes: Organised in co-operation with DEKS. Participation in all rounds is required. Register orders before the end of December.

2754 Faecal elastase (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 2 lyophilised faecal specimens, 0.5 mL.

Examinations: Elastase.

2150 Haemoxymeters

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | • • •

Specimens: 2 liquid (1.2 mL) samples.
Examinations: FO2Hb, FCOHb, FMETHb, ctHb, sO2.

Notes: Order one sample set for each analyser.

8816 Homocysteine (DEKS)

1 | Four rounds per year.

Specimens: 2 plasma samples 1 mL each.
Examinations: P-Homocysteine.

Notes: Organised in co-operation with DEKS. Participation in all rounds is required. All samples are distributed in February. Register orders before the end of December.

NEW

2755 Biochemical indicators of vitamin B12 deficiency (HoloTC, MMA, Homocysteine)

3 | 1 2 3 4 5 6 7 8 9 10 11 12 | • •

Specimens: 2 lyophilised serum samples, 2 mL.

Examinations: Holotranscobalamin (HoloTC), Methylmalonic Acid (MMA), Homocysteine.

8853 Iohexol (EQUALIS)

1 | Four rounds per year.

Specimens: Two plasma samples.
Examinations: P—Iohexol, Pt—GFR (Iohexol) absolute, Pt—GFR (Iohexol) relative.

Notes: Organised in cooperation with Equalis. Participation in all rounds is required. Register orders before the end of December.

8815 Methylmalonic acid (DEKS)

1 | Four rounds per year.

Specimens: 2 serum samples 1.5 mL each.
Examinations: S-Methylmalonat.

Notes: Organised in cooperation with DEKS. Participation in all rounds is required. All samples are distributed in February. Register orders before the end of December.

2651 Nasal swab cells

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | •

Specimens: 4 digital images of May-Grunwald-Giemsa-stained samples.

Examinations: Nasal cells.

NEW

2709 Phosphatidyl ethanol in blood (PEth)

3 | 1 2 3 4 5 6 7 8 9 10 11 12 | • • •

Specimens: 3 whole blood samples.

Examinations: Phosphatidyl ethanol (PEth) 16:0/18:1

2652 Sputum cells

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | •

Specimens: 4 digital images of May-Grunwald-Giemsa-stained samples.

Examinations: Sputum cells.

2640 Synovial fluid crystals

3 | 1 2 3 4 5 6 7 8 9 10 11 12 | • •

Specimens: 2-3 slides prepared from patient samples.

Examinations: Monosodium urate monohydrate and calcium pyrophosphate dihydrate crystals.

2410 Therapeutic drugs (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•			•			•	

Specimens: 2 liquid or lyophilised human serum samples, 5 mL.

Examinations: Amikasin, amitriptyline, carbamazepine, carbamazepine free, cyclosporine, digoxin, disopyramide, ethosuximide, flecainide, gentamycin, lidocaine, lithium, methotrexate, NAPA, netilmycin, nortriptyline, paracetamol (acetaminophen), phenobarbital, phenytoin, phenytoin free, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, tricyclics, valproic acid, valproic acid free, vancomycin.

EQA³

2480 Vitamin A, E and D metabolites (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•							•	

Specimens: 2 liquid serum samples, 0.5 - 1 mL. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Vitamin A, vitamin E, 25(OH)D-vitamin, 1,25(OH)2-D-vitamin, pre- and/or post-analytical indicators.

Notes: Target values for 25(OH)D vitamin metabolite are provided.

EQA³

2481 Vitamin A, E and D metabolites, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
			•							•	

Specimens: 2 liquid human serum samples, 2 mL.

Notes: Only in connection with scheme 2480.

2525 5-hydroxyindoleacetic Acid (5-HIAA) (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 2 serum samples.

Examinations: 5-HIAA.

Clinical chemistry » Specific proteins

2020 C-reactive protein (CRP) for analysers (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•		•		•		•

Specimens: 2 plasma or serum samples, 1 mL.

Examinations: CRP.

Notes: Scheme is designed only for clinical chemistry analysers. Order scheme 2132 for POCT CRP meters. If you are not sure whether your device is a POCT meter or an analyser, please contact our customer service.

2132 C-reactive protein (CRP), POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•		•		•		•	•	

Specimens: 2 serum samples, 1 mL.

Examinations: CRP.

Notes: Only for quantitative POCT CRP meters. Not suitable for LumiraDx. If you are not sure whether your device is a POCT meter or an analyser, please contact our customer service.

POCT

2140 CDT, carbohydrate deficient transferrin (EQUALIS) (1)

1	2	3	4	5	6	7	8	9	10	11	12
Six rounds per year											

Specimens: 2 human plasma samples, varying concentration of CDT.

Examinations: CDT.

Notes: Organised in co-operation with Equalis. Participation in all rounds is required. Register orders before the end of December. Available only in the EU.

2751 Faecal calprotectin (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised faecal specimens, 0.5 mL.

Examinations: Calprotectin.

2281 Interleukin-6 (IL-6) (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised samples.

Examinations: IL-6.

2200 Lipids and lipoproteins (3)

EQA3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 2 fresh human serum samples, 0.5–1 mL. Pre- and/or postanalytical cases in part of the rounds.

Examinations: Cholesterol, HDL cholesterol, LDL cholesterol, Apolipoprotein A1, Apolipoprotein A2, Apolipoprotein B, triglycerides, pre- and/or postanalytical indicators.

Notes: Separate round for Lp(a), see scheme 2202.

2202 Lipoprotein a (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 1 liquid or lyophilised human serum preparation.

Examinations: Lp(a).

2280 Procalcitonin (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•				•			•			•

Specimens: 2 human serum-based lyophilised samples.

Examinations: Procalcitonin.

Notes: Only for quantitative methods.

2160 Proteins in cerebrospinal fluid (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•					•			

Specimens: 1 cerebrospinal fluid sample 1-3 mL and 1 human serum sample, 1 mL.

Examinations: Cerebrospinal fluid: Albumin, IgG, total protein, IgG index. Serum: Albumin, IgG.

2240 Proteins, electrophoresis (3)

EQA3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 liquid or lyophilised human serum samples, 1 mL Pre- and/or post-analytical cases in part of the rounds.

Examinations: Electrophoresis, contains immunofixation, pre- and/or postanalytical indicators.

2230 Proteins, immunochemical determinations (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•		•			•			

Specimens: 2 liquid human serum samples, 1 mL.

Examinations: Alpha-1-antitrypsin, alpha-2-macroglobulin, albumin, ceruloplasmin, complement C3, complement C4, haptoglobin, hemopexin, IgA, IgG, IgLcKappa, IgLcLambda, IgLcKappa free, IgLcLambda free, IgM, orosomucoid, pre-albumin, RBP, transferrin, transferrin receptor.

Clinical chemistry » Tumour markers

2703 Anti-Müllerian hormone (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 liquid human serum samples, 1 mL.

Examinations: Anti-Müllerian hormone.

2226 Prostate specific antigen (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•			•			•		

Specimens: 2 serum samples, 1 mL.

Examinations: PSA, complexed PSA, free PSA, free/total PSA ratio.

2700, 2700S Tumour markers (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 liquid human serum samples, 2 mL.

Examinations: AFP, CA 125, CA 153, CA 199, CEA, ferritin, hCG (total, intact, beta-subunit), PSA, PSA free, PSA free/total index, TG, TG antibodies, beta-2-microglobulin, NSE, HE4.

Notes: 2700S is a limited version of the scheme available for laboratories performing testing of 1–5 analytes. Product 2700S does not include reporting from multiple analysers or methods.

2701 Tumour markers, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 liquid human serum samples, 2 mL.

Notes: Only in connection with scheme 2700.

2707 Maternal screening (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 2 lyophilised samples.

Examinations: AFP, b-hCG, inhibini A, PAPP-A, total hCG, unconjugated estriol.

Clinical chemistry » Urine analysis

8855 Alcohol biomarkers in urine (EQUALIS) (1)

1	2	3	4	5	6	7	8	9	10	11	12
Six rounds per year.											

Specimens: Urine sample.

Examinations: U-Ethyl glucuronide (EtG), U-Ethyl sulphate (EtS).

Notes: Organised in co-operation with Equalis. Participation in all rounds is required. Register orders before the end of December.

3240 Albumin and creatinine in urine (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

POCT

Specimens: 2 liquid human urine samples with spiked albumin and creatinine, 4 mL.

Examinations: Albumin, creatinine, albumin-creatinine ratio.

Notes: Only for quantitative methods.

3270 Pregnancy test (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

POCT

Specimens: 2 fresh urine samples, 1 mL.

Examinations: Qualitative hCG.

Notes: For clinical laboratories and POCT sites.

3300 Drug of abuse screening in urine (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•				•			•			

POCT

Specimens: 2 human-based urine samples, 5 mL.

Examinations: Alpha-PVP, Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cannabinoids, Carbamazepine, Cocaine +metabolites, Codeine, Dextropropoxyphene, EDDP, Fencyclidine, Fentanyl, Gammahydroxybutyrate (GHB), Ketamine, LSD, MDMA, MDPV, Metamphetamine, Methaqualone, Methadone +metabolites, Methylphenidate, Morphine, Opiates Oxycodone, Paracetamol, Pregabalin, Salicylate, Tricyclic- antidepr. Tramadol.

Notes: For clinical laboratories and POCT sites. Expert laboratory confirmatory results are provided. Results are reported as positive or negative.

3170 Urine bacterial screening with automated analysers (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•				•			•	

Specimens: 1 liquid sample and lyophilised synthetic urine sample containing bacteria.

Examinations: Bacterial, erythrocytes and leukocytes counting.

3200 Urine, identification of cells and other particles (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 4 digital images.

Examinations: Identification of cells and other particles.

3160 Urine quantitative chemistry (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

Specimens: 1 liquid urine, 10 mL.

Examinations: Albumin, amylase, calcium, chloride, cortisol-free, creatinine, glucose, inorganic phosphate, magnesium, osmolality, pH, potassium, protein, relative density, sodium, urea, uric acid.

POCT EQA³

3100 Urine strip test A (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•				•		•		

Specimens: 1 lyophilised urine sample with varying concentrations, 15 mL.

Examinations: Glucose, ketone bodies, leukocytes, nitrite, pH, protein, blood (erythrocytes), relative density.

Notes: For clinical laboratories and POCT sites. Water for dissolution available, see scheme 3101, should be ordered separately.

POCT EQA³

3102 Urine strip test A (incl. Bilirubin & Urobilinogen) (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•		•				•		•		

Specimens: 1 lyophilised urine sample with varying concentrations, 15 mL.

Examinations: Bilirubin, glucose, ketone bodies, leukocytes, nitrite, pH, protein, blood (erythrocytes), relative density, urobilinogen.

Notes: For clinical laboratories and POCT sites. Water for dissolution available, see scheme 3101, should be ordered separately.

3101 Urine strip test A, 15 mL water for sample dissolution

1	2	3	4	5	6	7	8	9	10	11	12
	•		•				•		•		

Specimens: 15 mL, water for dissolution of samples of scheme 3100 and 3102.

Notes: Only in connection with scheme 3100 and 3102.

EQA³

3130 Urine strip test B, particle count and estimation of density (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

Specimens: 1 lyophilised urine, 15 mL.

Examinations: Particle count: erythrocytes and leukocytes. Estimation of density: creatinine, relative density, osmolality. Strip tests: glucose, ketone bodies, leukocytes, nitrite, pH, protein, blood (erythrocytes).

Notes: Also suitable for automatic analysers (erythrocytes and leukocytes counting). The arbitrary concentrations of the obtained strip test results will only be collected in order to avoid different groupings of positive categories used by different strip tests and user laboratories. Water for dissolution of the lyophilised sample available, see scheme 3131, should be ordered separately.

3131 Urine strip test B, 15 mL water for sample dissolution

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

Specimens: 15 mL water for dissolution of lyophilised samples of scheme 3130.

Notes: Only in connection with scheme 3130.

Noklus Patient Median (NOPAM)

From 1 June, 2024, Noklus started the operation of NOPAM, a more user-friendly and improved version of the "percentile and flagger" program. Participants previously enrolled in the "percentile and flagger" program were automatically transferred to NOPAM. From the same date, new participants were able to register.

What is NOPAM?

NOPAM is a program for internal and external quality assessment based on patient results, offered by Noklus to medical laboratories worldwide. Laboratories participating in the program regularly send a standardized report containing the patient median and percentage of patient results above and below the laboratory's own reference limits. The report also includes the number of results used to calculate the various parameters. Results are calculated per instrument. Preferably, data is calculated from patient results for the out-patient population. It is possible to participate only with patient medians. Upon initial registration and whenever changes occur, the following information is recorded; contact information for the laboratory, country, patient population, sample material, sampling conditions, methods, instrument information (supplier, model, and type) and factors for factorization of analytes. The reagent lot number can either be included in the results report or entered manually by the laboratory. If the lot number is registered manually, it is sufficient to register when the lot changes.

How to use the results?

NOPAM can be a valuable tool to monitor analytical quality. The program can reveal important differences between different instrument types and methods, as well as monitor the progress of harmonization and standardization efforts. Participants can compare their own results with other comparable groups and compare different method groups. They can also compare their own results for all their own instruments, in case a bias is introduced, the laboratories monitor how the proportion of results above and below reference limits shifts. Results are presented in box plots or as a trend line with time on the x-axis.

What do you have to do to participate in NOPAM?

Laboratories that wish to participate must contact Noklus, who will send a protocol describing how results are reported.

Eva Rønneseth
Program coordinator
eva.ronneseth@noklus.no

Anne Elisabeth Solsvik
Program manager
anne.elisabeth.solsvik@noklus.no

Analytes included in the program

25-Hydroxyvitamin D
Albumin
ALP
ALT
AST
Bilirubin (total)
BUN
Ca
Cholesterol
Cl
Creatinine
CRP
Ferritin
Folate (B9)
FT4
GGT
Glucose
Hb
HbA1c
HDL-cholesterol
IgA
IgG
IgM
K
LDL-cholesterol
LDH
MCV
Mg
Na
Phosphate
PLT
Protein (total)
PSA
PTH
RBC
Triglycerides
TSH
Urea
Uric acid
Vitamin B12
WBC

Haematology

The haematology selection consists of schemes for blood transfusion serology, cell count and morphology as well as coagulation tests. Specialties include the Erythrocyte sedimentation rate for Alifax as well as the White blood cell count and INR schemes for POCT. Units performing blood transfusions find EQA schemes for hepatitis B and C, HIV as well as other infectious diseases under the microbiology portfolio. Schemes related to blood parasites can be found under the parasites chapter.

Haematology » Blood transfusion serological tests

4420 ABO and Rh grouping

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | • • • •

Specimens: 2 whole blood samples, 4 mL.

Examinations: ABO & Rh reaction strengths and interpretation.

Notes: There is possibility to insert results for full ABO RhD group, confirmation group without using the plasma and a group for a newborn.

4460 Antibody screening and compatibility testing (Requires ordering of product 4420)

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | • • • •

Specimens: 2 whole blood samples (4 mL) and 4 red blood cell suspensions (3 mL).

Examinations: Reaction strengths and interpretation.

4440 Antiglobulin test, direct

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | • • • •

Specimens: 2 red blood cell suspensions, 3 mL.

Examinations: Reaction strengths and interpretation.

EQA³

4480 Column agglutination methods: grading of reactions and patient cases

3 | 1 2 3 4 5 6 7 8 9 10 11 12 | •

Specimens: 3-5 cases and digital images (DiaMed and Grifols cards).

Examinations: Interpretation of the cases and reaction strengths of the digital images.

Notes: Post-analytical scheme.

8852 Titration of erythrocyte antibodies (EQUALIS)

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | One round per year.

Specimens: The test material is plasma for titration against included and own test erythrocytes.

Examinations: Titration 1. Ref.erythrocyte + ref.method, titration 2. Own testery. + ref. method, titration 3. Ref.erythrocyte + own method, titration 4. Own testery. + own method.

Notes: Organised in co-operation with Equalis. Participation in all rounds is required. Register orders before the end of December.

8851 Titration of ABO antibodies (EQUALIS)

1 | 1 2 3 4 5 6 7 8 9 10 11 12 | One round per year.

Specimens: The test material is plasma for titration against included test erythrocytes.

Examinations: Anti-A (titer), Anti-B (titer).

Notes: Organised in co-operation with Equalis. Participation in all rounds is required. Register orders before the end of December.

Haematology » Cell count and cell morphology

4100 Basic blood count, 1-level sample

3

1	2	3	4	5	6	7	8	9	10	11	12
•	•	•	•	•	•	•	•	•	•	•	•

Specimens: 1 blood cell suspension, 3 mL.

Examinations: Hb, HCT, MCH, MCHC, MCV, PLT, RBC, RDW (red cell distribution width), WBC, cumulative patient means of MCH, MCHC, MCV.

Notes: Not suitable for PixCell Medical HemoScreen analyser.

4110 Basic blood count, 2-level samples

3

1	2	3	4	5	6	7	8	9	10	11	12
•	•	•	•	•	•	•	•	•	•	•	•

Specimens: 2 blood cell suspensions, 3 mL.

Examinations: Hb, HCT, MCH, MCHC, MCV, PLT, RBC, RDW (red cell distribution width), WBC, cumulative patient means of MCH, MCHC, MCV.

Notes: Not suitable for PixCell Medical HemoScreen analyser.

4180 Leucocyte differential count and evaluation of blood cell morphology

3

1	2	3	4	5	6	7	8	9	10	11	12
				•					•		

Specimens: 2–3 patient cases as virtual slide images.

Examinations: Leucocyte differential count and evaluation of red blood cells.

4200, 4201 Leucocyte differential count, 3-part, automated

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Analyser specific product codes:
4200: ABX, Advia, Cell-Dyn, Coulter, Medonic, Mindray, Nihon Kohden Celltac MEK
4201: Sysmex

Specimens: 1 blood cell suspension, 2–4 mL.

Examinations: Absolute numbers of leucocytes, lymphocytes, mononuclear cells and granulocytes.

4230-4240 Leucocyte differential count, 5-part, automated

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Analyser specific product codes:
4230: Siemens Advia
4233: Sysmex XE, XS, XT, XN
4236: Mindray
4240: Coulter DxH 500 series
4232: Coulter
4234: ABX Pentra, Yumizen
4237: Nihon Kohden Celltac MEK

Specimens: 1 blood cell suspension, 2–4 mL.

Examinations: Leucocytes, basophils, eosinophils, granulocytes, lymphocytes and monocytes.

Notes: More information about the suitability of the product for your device from the EQA Coordinator.

4150, 4153, 4154 Reticulocyte count, automated

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Analyser specific product codes:
4150: Siemens Advia, Beckman Coulter
4153: Sysmex
4154: ABX Pentra

Specimens: 2 stabilised red blood cell suspensions, 2–4 mL.

Examinations: Reticulocyte count, absolute values.

Notes: More information about the suitability of the product for your device from the EQA Coordinator.

4140 Reticulocyte count, manual methods

1

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 1 stabilized red blood cell suspension, 2 mL.

Examinations: Reticulocyte count.

4130 White blood cell count: HemoCue, POCT

3

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 1 blood cell suspension, 2 mL.

Examinations: Leucocytes.

Notes: The scheme is for HemoCue WBC Systems.

POCT

Haematology » Coagulation

4330 Activated partial thromboplastin time, INR and fibrinogen (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised plasma samples, 0.5–1 mL.

Examinations: APTT, fibrinogen and Prothrombin time (INR, PT% and PT in seconds).

4387 Anticoagulants: LMW-Heparin/antiFXa (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised plasma samples, 0.5–1 mL.

Examinations: LMW-heparin/antiFXA.

POCT

4388 D-dimer (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 plasma samples, 0.5 mL.
Examinations: D-Dimer.

Notes: For clinical laboratories and POCT sites.

4389 D-dimer, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 plasma samples, 0.5 mL.
Examinations: D-Dimer.

Notes: Only in connection with scheme 4388.

POCT

4335 INR, Coagucheck, i-STAT, Siemens Xprecia, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: Liquid plasma sample.
Examinations: Prothrombin time in INR unit.

Notes: Only for CoaguChek, i-STAT and Siemens Xprecia meters.

POCT

4337 INR, EuroLyzer, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: 1 lyophilised plasma sample.
Examinations: Prothrombin time in INR unit.

Notes: Only for EuroLyzer INR meter.

POCT

4340 INR, LabPad, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: 1 lyophilised whole blood sample.
Examinations: Prothrombin time in INR unit.

Notes: Only for LabPad INR meters.

POCT

4338 INR, MicroINR, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: 1 lyophilised whole blood sample.
Examinations: Prothrombin time in INR unit.

Notes: Only for microINR, LumiraDX and CoagSense meters.

4300 Prothrombin time (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised plasma samples, 0.5–1 mL.

Examinations: Prothrombin time (INR, PT% and PT in seconds).

4386 Special coagulation (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised plasma samples, 0.5–1 mL.

Examinations: Thrombin time, Antithrombin, Factor VIII, Protein C, Protein S.

EQA schemes for blood banks

Blood transfusion serology

4420	ABO and Rh grouping
4460	Antibody screening and compatibility testing
4440	Antiglobulin test, direct
4480	Column agglutination methods: grading of reactions and patient cases

Bacterial serology

5880	Syphilis serology

Bacteriology

5100	Blood culture
5101	Blood culture, screening

Virology, serological tests

5650	Cytomegalovirus, antibodies
5092	Hepatitis A, antibodies
5093	Hepatitis B, s-antigen antibodies, quantitative
5094-5096	Hepatitis B and C, serology
5091	HIV, antibodies and antigen detection
5089	Human T-cell lymphotropic virus, antibodies
5660	Parvovirus B19, antibodies

Virology, molecular tests

5679	Hepatitis B virus, nucleic acid detection (DNA)
5678	Hepatitis C virus, nucleic acid detection (RNA)
5680	HIV-1, nucleic acid detection (RNA)

EQA services for POCT sites

Patient outcome is associated with obtaining a reliable test result regardless of where the testing is performed. To ensure high quality of care and patient safety, it is imperative that point-of-care testing (POCT) is subjected to the same quality requirements as conventional laboratory analyses.

We offer a range of EQA schemes suitable for POCT sites. These services are intended for all testing units including home/community nursing, hospital wards, pediatric clinics, surgical units, occupational healthcare, outpatient clinics and medical centers.

Clinical chemistry

2610	Acid-base status and electrolytes
3240	Albumin and creatinine in urine
2100	Basic chemistry, POCT analysers
2132	C-reactive protein (CRP), POCT
3300	Drug of abuse screening in urine
2750	Faecal occult blood, qualitative
2749	Faecal occult blood, quantitative
2570, 2580, 2590	Glucose meters
1263	Haemoglobin A1c, liquid samples, POCT
2114	Haemoglobin, 1-level, POCT
2115	Haemoglobin, 1-level HemoCue 801 and HemoCue 301
2112	Haemoglobin, 3-level samples, POCT
2526	Ketones (beta-hydroxybutyrate), POCT
2690	Natriuretic peptides 1, B-type, NT-ProBNP
2691	Natriuretic peptides 2, B-type, BNP
3270	Pregnancy test
2530	Troponin I and Troponin T, detection, POCT
3100	Urine strip test A

Haematology

4388	D-Dimer
4335	INR, CoaguChek, i-STAT and Siemens Xprecia, POCT
4337	INR, EuroLyzer, POCT
4340	INR LAbPad, POCT
4338	INR, MicroINR, LumiraDX and CoagSense, POCT
5430	Malaria, antigen and nucleic acid detection
4130	White blood cell count: HemoCue, POCT

Microbiology

5635	Dengue virus, antibodies and antigen detection
5640	EBV mononucleosis, POCT
5689	HCV RNA from capillary blood, POCT
5860	*Helicobacter pylori*, antibodies
5596	*Helicobacter pylori*, antigen detection in faeces
5090	HIV, antibodies and antigen detection, POCT
5687	HBsAg and HCVAb POCT
5671	Influenza virus A+B, antigen detection
5597	Legionella, antigen detection in urine
5430	Malaria, antigen and nucleic acid detection
5980	*Mycoplasma pneumoniae*, antibodies
5686	Norovirus, antigen detection
5560	Puumala virus, antibodies
5673	Respiratory adenovirus, antigen detection
5098	Rotavirus and adenovirus, antigen detection
5672	RS virus, antigen detection
5681	SARS-CoV-2 antigen detection
5676	SARS-CoV-2 nucleic acid detection
5595	*Streptococcus pyogenes* (Group A), detection in pharyngeal sample
5599	*Streptococcus agalactiae* (GBS), nucleic acid detection
5598	*Streptococcus pneumoniae*, antigen detection in urine
5099	Tick-borne encephalitis virus, antibodies
5473	*Trichomonas vaginalis*, detection

Preanalytics

7801	Preanalytics, urine and blood sample collection
7804	Preanalytics, POCT in chemistry

Immunology

This program includes schemes for immunodiagnostic tests such as those for coeliac disease, rheumatoid factor and thyroid gland autoantibodies. For allergy diagnostics, review the allergology program in the clinical chemistry portfolio.

5935 ANCA and GbmAb

3

1	2	3	4	5	6	7	8	9	10	11	12
	•						•				

EQA³

Specimens: 2 plasma or serum samples 0.5 mL.

Examinations: Anti-neutrophilic cytoplasmic Ab and Immunofluorescent test for ANCA, Myeloperoxidase Ab, Proteinase-3 Ab and Glomerular basement membrane Ab. Pre- and/or post-analytical cases in part of the rounds.

Notes: Quantitative results are also processed (Pr3Ab, MPOAb, GbmAb).

5900 Antinuclear antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

EQA³

Specimens: 3 plasma or serum samples, 0.6 mL.

Examinations: ANA, ENAAb, RNPAb, SmAb (SmDAb and/or SmBAb), SSAAb, SSBAb, Scl70Ab, CENP-B, CENP-A, Jo1Ab, dsDNA, HistAb, RibP Ab, RNApol III Ab. Pre- and/or post-analytical cases in part of the rounds.

Notes: Extractable antinuclear antigens and double-stranded deoxyribonucleic acid are included.

5938 Autoimmune diagnostics, IFA interpretation

3

1	2	3	4	5	6	7	8	9	10	11	12
				•							

Specimens: 3 cases (digital images).

Examinations: Interpretation (ANA, ANCA and EMA images).

5930 Autoimmune liver disease and gastric parietal cell antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: 2 plasma or serum samples, 0.4 mL.

Examinations: LKM-1 antibodies, SMA, AMA, PCA (GPCA).

5940 Coeliac disease, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	•				•				•		

EQA³

Specimens: 2 plasma or serum samples, 0.7 mL.

Examinations: Endomysium antibodies, tissue transglutaminase antibodies, deamidated gliadin peptide antibodies, interpretation of the Total IgA concentration of the sample. Pre- and/or post-analytical cases in part of the rounds.

Notes: Quantitative results are also processed (tTGAbA, tTGAbG, DGPAbA, DGPAbG). Scheme is not suitable for POCT.

5250 Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis*

3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

EQA³

Specimens: One sample set (contains 3 lyophilised samples, 1 liquid blank/NIL sample and water to dissolve the samples) and a preanalytical case description including questions.

Examinations: Quantitative result and qualitative interpretation of TbINFg. The scheme is not suitable for TB ELISpot assays.

5251 Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis* - whole blood

3

1	2	3	4	5	6	7	8	9	10	11	12
				•							

Specimens: 2 Li-heparin whole blood samples.

Examinations: Quantitative results and qualitative interpretation of TbINFg. The product is not intended for TB ELISpot assays or VIDAS TB-IGRA (TBRA) test.

Notes: EQA samples must be aliquoted into to test specific tubes (not provided) within 48h of phlebotomy. The samples are sent directly to the participating laboratories by the sample provider. By placing the order for this round, the participants give their consent to Aurevia to transfer the participant contact information to the sample provider for shipping purposes.

5937 Phospholipid antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•							

Specimens: 2 plasma or serum samples 0.5 mL.

Examinations: Phospholipid antibody screen (aCL/B2GPI, aCL IgG/IgM antibodies, B2GPI IgG/IgM antibodies), Cardiolipin antibodies (IgG and IgM), Beta-2-glycoprotein I antibodies (IgG and IgM).

Notes: Quantitative results are also processed.

5820 Rheumatoid factor and cyclic citrullinated peptide antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 liquid or lyophilised serum or plasma samples, 0.7 mL.

Examinations: Qualitative and quantitative RF, CCPAb.

5920 Thyroid gland antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•			•				•		

Specimens: 2 plasma or serum samples 0.4 mL.

Examinations: Thyroglobulin antibodies and thyroid peroxidase antibodies.

Notes: Quantitative results are also processed.

5913 TSH receptor antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•							•		

Specimens: 2 plasma or serum samples, 0.4 mL.

Examinations: Thyroid stimulating hormone receptor antibodies.

Notes: Quantitative results are also processed.

Microbiology

The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in the areas of bacterial serology, bacteriology, mycology, parasitology and virology. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, and PCR tests, solutions for versatile needs are available. Authentic single donor samples are included in multiple schemes.

Microbiology » Bacterial Serology

5840 Antistreptolysin (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 human single donor plasma or serum samples, 0.4 mL.

Examinations: Qualitative and quantitative ASO.

5950 *Bordetella pertussis*, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•				•			•	

Specimens: 2 plasma or serum samples, 0.3 mL.

Examinations: *B. pertussis* IgA, IgG & IgM antibodies, Pertussis toxin IgA, IgG & IgM, post-analytical clinical interpretation.

EQA³

5960 *Borrelia burgdorferi*, antibodies, European origin (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•				•			•	

Specimens: 2 human single donor plasma or serum samples, 0.5 mL.

Examinations: *B. burgdorferi* IgG, IgM and total antibodies, post-analytical clinical interpretation.

EQA³

5850 *Brucella* antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 2 plasma or serum samples, 0.5 mL.

Examinations: *Brucella* IgG, IgM and total antibodies.

5965 CXCL 13 Chemokine (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 liquid samples.

Examinations: Chemokine CXCL13 detection.

5620 *Chlamydia pneumoniae*, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 plasma or serum samples, 0.4 mL.

Examinations: *C. pneumoniae* IgA, IgG, IgM antibodies, post-analytical clinical interpretation.

EQA³

5851 *Francisella tularensis*, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 3 plasma or serum samples, 0.5 mL.

Examinations: *Francisella tularensis* IgG, IgM and total antibodies.

5860 *Helicobacter pylori*, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 plasma or serum samples, 0.4 mL.

Examinations: *H. pylori* IgA, IgG and total antibodies, quantitative and qualitative tests, post-analytical clinical interpretation.

Notes: For clinical laboratories and POCT sites.

POCT

EQA³

EQA³ POCT

5980 *Mycoplasma pneumoniae*, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•		•	

Specimens: 2 human single donor plasma or serum samples, 0.3 mL.

Examinations: *M. pneumoniae* IgG, IgM and total antibodies, post-analytical clinical interpretation.

Notes: For clinical laboratories and POCT sites.

EQA³

5880 Syphilis serology (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•				•				•		•

Specimens: 2 human single donor serum samples, 0.6 mL.

Examinations: Cardiolipin, *Treponema pallidum* antibodies, post-analytical clinical interpretation.

Microbiology » Bacteriology

5050 Bacteriological staining, direct (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 3 cases, 3–9 digital images.

Examinations: Interpretation of digital images taken from the direct bacteriological Gram staining of clinical samples.

5100 Blood culture (incl. sepsis multiplex methods) (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•					•		•

Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and clinical strains.

Examinations: Culture, identification, antimicrobial susceptibility testing. Direct nucleic acid detection from positive blood culture bottles by multiplex methods is included in the scheme.

Notes: Fresh blood is needed but not included in the shipment.

5101 Blood culture, screening (incl. sepsis multiplex methods) (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•					•		•

Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation.

Examinations: Culture, preliminary identification using Gram staining and/or direct nucleic acid detection from positive blood culture bottles by multiplex methods. The scheme is also suitable for stem cell banks screening only for possible growth.

Notes: Fresh blood is needed but not included in the shipment.

NEW

5241 *Bordetella pertussis/parapertussis*, nucleic acid detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
				•					•		

Specimens: 2 artificial samples, 1 mL.

Examinations: Detection of *B. pertussis* and *B. parapertussis* nucleic acid.

5150 Cerebrospinal fluid, bacterial culture (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 2 lyophilised samples. Brief case histories are also given.

Examinations: Culture and identification. The scheme is also suitable for laboratories performing screening and reporting merely a preliminary identification.

Notes: See also scheme 5303 Meningitis-encephalitis multiplex, nucleic acid detection.

5612 *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, nucleic acid detection (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•			•			•	

Specimens: 3 simulated swab/urine samples, 2 mL.

Examinations: Detection of *C. trachomatis* and *N. gonorrhoeae* nucleic acid.

Notes: See also scheme 5302 Sexually transmitted diseases multiplex, nucleic acid detection. The samples contain hDNA.

5200 *Clostridioides difficile*, culture and toxin detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised mixtures of bacteria.

Examinations: This scheme includes *C. difficile* culture, antigen detection (GDH), toxin detection and direct nucleic acid detection. Hypervirulent *C. difficile* strains also included.

5202 *Clostridioides difficile*, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised mixtures of bacteria.

Notes: Only in connection with scheme 5200.

5201 *Clostridioides difficile*, nucleic acid detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 lyophilised mixtures of bacteria.

Examinations: *C. difficile* direct nucleic acid detection. Hypervirulent *C.difficile* strains also included.

Notes: 5200 includes also this examination.

5191 Faecal bacterial pathogens multiplex, nucleic acid detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
			•		•				•		•

Specimens: 3 samples. Either lyophilised mixtures of bacteria and/or simulated samples, 1 mL.

Examinations: Direct nucleic acid detection. Pathogens included are *Aeromonas*, *Campylobacter*, *C. difficile*, *E. coli* EHEC (stx1/stx2), *E. coli* EAEC, *E. coli* EIEC, *E. coli* EPEC, *E. coli* ETEC, *Plesiomonas*, *Salmonella*, *Shigella*, *Vibrio* and *Yersinia*.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5190 Faecal culture (1)

1	2	3	4	5	6	7	8	9	10	11	12
			•		•				•		•

Specimens: 2 lyophilised mixtures of bacteria.

Examinations: Culture, identification and antimicrobial susceptibility (rounds 2 and 4). In addition to culture, samples are also suitable for direct nucleic acid detection. Pathogens included are *Aeromonas*, *Campylobacter*, *Plesiomonas*, *Salmonella*, *Shigella* and *Yersinia*.

5080 General Bacteriology 1 (aerobes and anaerobes) (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

EQA³

Specimens: 4 lyophilised mixtures of microbes: both pathogens and normal flora. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases.

Notes: 5080 includes 5081, General Bacteriology 2.

5081 General Bacteriology 2 (aerobes) (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

EQA³

Specimens: 2 lyophilised mixtures of microbes: both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases.

Notes: 5080 General Bacteriology 1 includes 5081.

5041 Gram stain, blood culture (1)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 air-dried, unfixed microbe suspensions on slides. Brief case histories also given.

Examinations: Staining and microscopy.

5040 Gram stain, colonies (1)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 3 air-dried, unfixed microbe suspensions on a slide.

Examinations: Staining and microscopy.

5043 Gram stain, vaginal fluid (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

NEW

Specimens: Digital images of three Gram-stained vaginal fluid samples with brief case histories.

Examinations: Evaluation of Gram-stained vaginal fluid.

5596 *Helicobacter pylori*, antigen detection in faeces (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

POCT

Specimens: 3 lyophilised feacal samples.

Examinations: *H. pylori* antigen detection.

Notes: For clinical laboratories and POCT sites.

5253 *Helicobacter pylori*, drug resistance, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 3 simulated swab samples.

Examinations: *H. pylori* nucleic acid detection, clarithromycin susceptibility.

POCT

5597 Legionella, antigen detection in urine

3

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

Specimens: 3 simulated urine samples.

Examinations: Legionella antigen detection.

5230 *Mycobacterium tuberculosis*, drug resistance, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 simulated samples, 1 mL.

Examinations: *Mycobacterium tuberculosis* nucleic acid detection, rifampicin susceptibility and isoniazid susceptibility.

5231 *Mycobacterium tuberculosis*, drug resistance, nucleic acid detection, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 simulated samples, 1 mL.

Notes: Only in connection with scheme 5230.

5220 Mycobacterial culture and stain

1

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 lyophilised samples and 2 fixed smears on slides.

Examinations: Detection of *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis* complex and atypical mycobacteria: culture, direct nucleic acid detection, acid-fast staining and microscopy.

Notes: See also products 5250 and 5251 IGRA for *M. tuberculosis*.

5221 Mycobacterial nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 lyophilised samples.

Examinations: Direct nucleic acid detection.

Notes: 5220 includes also his examination. For additional set of samples, order scheme 5222.

5222 Mycobacteria, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 lyophilised samples.

Notes: Only in connection with scheme 5220 or 5221.

5240 Mycobacterial stain

1

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 fixed smears on slides.

Examinations: Acid-fast staining and microscopy.

5254 *Mycoplasma genitalium*, drug resistance, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 simulated swab samples.

Examinations: *M. genitalium* nucleic acid detection, macrolide (azithromycin) susceptibility. Some rounds will include a fluoroquinolone (moxifloxacin) resistant sample.

Notes: The samples contain hDNA.

5120 *Neisseria gonorrhoeae* (Gc), culture and susceptibility testing

1

1	2	3	4	5	6	7	8	9	10	11	12
		•		•			•			•	

Specimens: 2 lyophilised mixtures of microbes. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.

Examinations: Culture, identification and antimicrobial susceptibility testing. Also suitable for laboratories performing preliminary screening.

5180 Salmonella, culture

1

1	2	3	4	5	6	7	8	9	10	11	12
			•		•				•		•

Specimens: 2 lyophilised mixtures of bacteria.
Examinations: Culture.

Notes: 5190 also includes 5180.

5594 *Streptococcus agalactiae* (GBS), culture

1

1	2	3	4	5	6	7	8	9	10	11	12
			•		•			•		•	

Specimens: 2 lyophilised samples. Samples include pathogens and/or normal flora.
Examinations: Culture.

Notes: See also product 5599 for direct *S. agalactiae* nucleic acid detection from sample.

5599 *Streptococcus agalactiae* (GBS), nucleic acid detection

3

POCT

1	2	3	4	5	6	7	8	9	10	11	12
			•		•			•		•	

Specimens: 2 swab samples. Samples also include normal flora.
Examinations: Direct nucleic acid detection.

Notes: The samples contain hDNA. See also product 5594 for *S. agalactiae* (GBS) culture.

5598 *Streptococcus pneumoniae*, antigen detection in urine

3

POCT

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

Specimens: 3 simulated urine specimens.

Examinations: *S. pneumoniae* antigen detection.

5595 *Streptococcus pyogenes* (Group A), detection in pharyngeal sample

3

POCT

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•			•

Specimens: 3 simulated pharyngeal samples.
Examinations: Strep A Ag, Strep A NAT.

Notes: For clinical laboratories and POCT sites.

5073 Surveillance for multidrug resistant bacteria, gramnegative rods

1

1	2	3	4	5	6	7	8	9	10	11	12
	•				•			•		•	

Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.

Examinations: The scheme is intended for laboratories performing screening of multidrug resistant gramnegative rods (e.g. CPE, ESBL, MDR *Acinetobacter* and *P. aeruginosa)* by culture and/or direct nucleic acid detection method.

5071 Surveillance for multidrug resistant bacteria, MRSA

1

1	2	3	4	5	6	7	8	9	10	11	12
	•				•			•		•	

Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.

Examinations: The scheme is intended for laboratories performing screening of MRSA (methicillin resistant *Staphylococcus aureus*) by culture and/or direct nucleic acid detection method.

5072 Surveillance for multidrug resistant bacteria, VRE

1

1	2	3	4	5	6	7	8	9	10	11	12
	•				•			•		•	

Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.

Examinations: The scheme is intended for laboratories performing screening of VRE (vancomycin-resistant enterococci) by culture and/or direct nucleic acid detection method.

5140 Throat streptococcal culture

1

1	2	3	4	5	6	7	8	9	10	11	12
		•		•			•			•	

Specimens: 3 lyophilised mixtures of bacteria.

Examinations: Culture and identification of group A, C and G streptococci.

5060 Urine culture, quantitative screening

EQA³

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 lyophilised samples and dilutor. Brief case histories also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Culture and quantitation, pre-and/or post-analytical indicators.

Notes: Scheme 3170 available for urine bacterial screening with automated analysers.

5065 Urine culture, quantitative screening, identification and susceptibility

EQA³

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 2 lyophilised samples and dilutor. Brief case histories also given. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Culture, quantitation, identification and antimicrobial susceptibility testing, pre-and/or post-analytical indicators.

Notes: Scheme 3170 available for urine bacterial screening with automated analysers.

Microbiology » Mycology

5260 Fungal culture

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 3 lyophilised samples. Brief case histories also given. The samples may include moulds, dermatophytes and yeasts.

Examinations: Culture and identification. Antimicrobial susceptibility testing of yeast strains.

5261 Fungal infections, nucleic acid detection

1	2	3	4	5	6	7	8	9	10	11	12
			•					•			

Specimens: 3-4 simulated samples. The samples may include yeasts, dermatophytes and moulds.

Examinations: Nucleic acid detection according to laboratory's own test selection.

Notes: Test selection of the participating lab is taken into consideration in result processing. The samples contain hDNA.

Microbiology » Parasitology

5472 Faecal parasites multiplex, nucleic acid detection

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 lyophilised samples.

Examinations: Nucleic acid detection of *Cryptosporidium, Dientamoeba fragilis, Entamoeba histolytica* and *Giardia lamblia.*

5430 Malaria, antigen and nucleic acid detection

POCT

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 whole blood samples. The scheme contains primarily *Plasmodium falciparum* positive and negative samples, occasionally other *Plasmodium* species are included.

Examinations: Antigen and nucleic acid detection. Target antigens: HRP2 and/or pLDH and/or aldolase.

Notes: For clinical laboratories and POCT sites.

5462 Malaria screening, Giemsa stain

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.

Examinations: Preliminary screening of malaria plasmodia.

5463 Malaria screening, MGG stain

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.

Examinations: Preliminary screening of malaria plasmodia.

5460 Parasites in blood, Giemsa stain

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites.

5461 Parasites in blood, MGG stain (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites.

5440 Parasites in faeces (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 stool samples in formalin. Brief case histories also given.

Examinations: Screening and identification of intestinal parasites (ova and parasites).

5450 Parasites in faeces, virtual microscopy (5)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: Virtual whole slide images of stool samples in formalin prepared by using a scanner microscope. Brief case histories also given.

Examinations: Screening and identification of intestinal parasites (ova and parasites).

5420 Toxoplasma, antibodies (3)

EQA³

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human single donor plasma samples, 0.7 mL. Brief case histories also given.

Examinations: Toxoplasma IgG, IgM and total antibodies, IgG avidity, postanalytical clinical interpretation.

5473 *Trichomonas vaginalis*, detection (3)

POCT

1	2	3	4	5	6	7	8	9	10	11	12
	•		•				•		•		

Specimens: 2 simulated samples.

Examinations: Detection of Trichomonas vaginalis antigen and nucleic acid (NAT).

Notes: The samples contain hDNA.

Microbiology » Virology

5651 CMV and EBV, nucleic acid detection, quantitative (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•							•		

Specimens: 5 samples simulating plasma, 1.5 mL.

Examinations: CMV and EBV NAT (quantitative).

Notes: Quantitative result processing.

5650 Cytomegalovirus, antibodies (3)

EQA³

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 3 human single donor plasma samples, 0.7 mL.

Examinations: Cytomegalovirus IgG, IgM and total antibodies, IgG avidity and post-analytical clinical interpretation.

5635 Dengue virus, antibodies and antigen detection (3)

EQA³ POCT

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•		•	

Specimens: 3 human single donor plasma or serum samples, 0.5 mL. Occasionally simulated samples.

Examinations: Dengue virus IgG and IgM antibodies, Dengue virus antigen (NS1) and post-analytical clinical interpretation.

5640 EBV mononucleosis, POCT (3)

POCT

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 3 human single donor plasma samples, 0.5 mL

Examinations: MonAb.

Notes: For clinical laboratories and POCT sites.

5641 EBV mononucleosis, specific antibodies (3)

EQA³

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 3 human single donor plasma samples, 1.4 mL.

Examinations: EBNA AbG, EBV VCA AbG, EBV VCA AbM, IgG Avidity and post-analytical clinical interpretation.

POCT

5687 HBsAg and HCVAb POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human plasma or serum samples, 0.5 mL.
Examinations: HBsAg, HCVAb POCT.

Notes: This scheme is only for POC tests. Scheme 5094-5096 is for clinical laboratories.

NEW
POCT

5689 HCV RNA from capillary blood, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
				•					•		

Specimens: To be announced.

Examinations: HCV NAT (RNA).

EQA³

5092 Hepatitis A, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human single donor plasma or serum samples, 0.6 mL.

Examinations: HAVAb, HAVAbM, HAVAbG and post-analytical clinical interpretation.

EQA³

5094–5096 Hepatitis B and C, serology, specimen volume 0.6 mL / 1.2 mL / 2.0 mL (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human single donor plasma or serum samples, 0.6 / 1.2 / 2 mL. Choose the sample volume according to your test selection.
Examinations: HBsAg, HBsAgCt, HBcAb, HBcAbM, HBeAb, HBeAg, HBsAb (qual), HCVAb, HCVAbCt, and post-analytical clinical interpretation.

Volume-specific product codes:
5094: 0.6 mL
5095: 1.2 mL
5096: 2.0 mL
Notes: For clinical laboratories. Scheme 5687 is for POCT users.

5093 Hepatitis B, s-antigen antibodies, quantitative (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 human single donor plasma or serum samples, 0.5 mL.

Examinations: HBsAb (anti-HBs), quantitative.

5679 Hepatitis B virus, nucleic acid detection (DNA) (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 3 lyophilised or liquid plasma samples, 1,5 mL.

Examinations: HBV DNA, quantitative and/or qualitative nucleic acid detection.

5678 Hepatitis C virus, nucleic acid detection (RNA) (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 3 lyophilised or liquid plasma samples, 1,1 mL.

Examinations: HCV RNA, quantitative and/or qualitative nucleic acid detection.

EQA³

5682 Hepatitis E, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: HEV Ab, HEV IgG, HEV IgM, post-analytical clinical interpretation.

5555 Herpes simplex 1 and 2, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human single donor plasma or serum samples, 0.5 mL. Occasionally simulated samples.

Examinations: HSV IgG (qualitative/quantitative), HSV IgM, HSV-1 IgG, HSV-2 IgG.

5680 HIV-1, nucleic acid detection (RNA) (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•				•		•	

Specimens: 3 lyophilised or liquid plasma samples, 1,5 mL.

Examinations: HIV-1 RNA, quantitative and/or qualitative nucleic acid detection.

5091 HIV, antibodies and antigen detection (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

EQA³

Specimens: 3 human plasma or serum samples, 0.7 mL.

Examinations: HIVAb (1/2), HIVAgAb (combo), HIVAg (p24), HIVAb confirmatory test and post-analytical clinical interpretation. Positive specimens may include HIV-1 or HIV-2.

5088 HIV, antibodies and antigen detection, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human plasma or serum samples, 0.7 mL.

Notes: Only in connection with scheme 5091.

5090 HIV, antibodies and antigen detection, POCT (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

POCT

Specimens: 3 human plasma or serum samples, 0.5 mL.

Examinations: HIVAb and HIVAgAb (combo) POCT.

Notes: This scheme is only for POC tests. Scheme 5091 is for clinical laboratories.

6801 HPV-related head and neck cancer control: HPV-NAT (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

NEW

Specimens: 2 cell-derived samples each including paraffin scrolls in a vial for NAT.

Examinations: Scrolls: HPV nucleic acid detection.

Notes: HPV NAT to be performed on paraffin scrolls. Please see full product 6800 in the Oncology section.

5556 HSV1&2/VZV/*Treponema pallidum*, nucleic acid detection (3)

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 3 samples simulating swab samples taken from lesions.

Examinations: Nucleic acid detection of HSV1, HSV2, VZV, *Treponema pallidum.*

Notes: The samples contain hDNA.

5086 Human papillomavirus, nucleic acid detection (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 2 simulated samples, 1 mL.

Examinations: High-risk human papillomavirus NAT (hrHPVNAT). HPV genotypes included are: 16, 18, 31, 33, 39, 45, 51, 52, 66, 67.

Notes: Suitable for nucleic acid methods used in cervical cancer screening. The samples contain hDNA.

5089 Human T-cell lymphotropic virus, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

EQA³

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: HTLVAb screening and confirmatory tests, post-analytical clinical interpretation. Positive samples may include HTLV-1 or HTLV-2.

5670 Influenza virus A+B and RS virus, nucleic acid detection (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•									•	

Specimens: 3 simulated samples, 1 mL.

Examinations: InfANAT, InfBNAT, RSVNAT.

Notes: See also scheme 5300 Respiratory infections multiplex, nucleic acid detection or 5562 Multiple respiratory virus, nucleic acid detection. The samples contain hDNA.

5671 Influenza virus A+B, antigen detection (3)

1	2	3	4	5	6	7	8	9	10	11	12
	•									•	

POCT

Specimens: 3 simulated samples.

Examinations: InfAAg, InfBAg.

Notes: For clinical laboratories and POCT sites. This scheme is only for antigen detection methods.

5668 Measles virus, antibodies (3)

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

EQA³

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: Measles virus IgG and IgM antibodies and post-analytical clinical interpretation.

5683 Mpox, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 2 swab samples simulating patient samples from lesions.
Examinations: Mpox NAT.

Notes: The samples contain hDNA.

5562 Multiple respiratory virus, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 3 simulated samples.
Examinations: Influenza A/B virus NAT, RSV NAT and SARS-CoV-2 NAT.

Notes: The scheme is not suitable for TMA methods (e.g. Hologic Aptima SARS-CoV-2 Assay). The samples contain hDNA.

EQA³

5669 Mumps virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: Mumps virus IgG and IgM antibodies and post-analytical clinical interpretation.

POCT

5686 Norovirus, antigen detection

1	2	3	4	5	6	7	8	9	10	11	12
		•			•		•			•	

Specimens: 3 simulated swab samples.

Examinations: Norovirus antigen detection, genogroups GI and GII.

5675 Norovirus, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 3 simulated samples, 1 mL.

Examinations: Norovirus nucleic acid detection, genogroups GI and GII.

EQA³

5660 Parvovirus (B19), antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 3 human single donor plasma or serum samples, 0.4 mL

Examinations: Parvovirus IgG, IgM, IgG avidity and post-analytical clinical interpretation.

POCT
EQA³

5560 Puumala virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•		•	

Specimens: 3 human single donor plasma or serum samples, 0.3 mL. Brief case histories are also provided.

Examinations: Puumala virus IgG, IgM, POC tests and specific antibodies, IgG avidity and post-analytical clinical interpretation.
Notes: For clinical laboratories and POCT sites.

5673 Respiratory adenovirus, antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 3 simulated samples, 1 mL.

Examinations: Adenovirus Ag.

5098 Rotavirus and adenovirus, antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 3 artificial faecal samples.

Examinations: Rotavirus and adenovirus antigen detection.

POCT

5672 RS virus, antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
	•									•	

Specimens: 3 simulated samples.
Examinations: RSVAg.

Notes: For clinical laboratories and POCT sites. This scheme is only for antigen detection methods.

5667 Rubella virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: Rubella virus IgG and IgM antibodies, IgG avidity and postanalytical clinical interpretation.

EQA³

5681 SARS-CoV-2, antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 3 simulated samples.

Examinations: SARS-CoV-2 Ag.

Notes: For clinical laboratories and POCT sites.

POCT

5676 SARS-CoV-2, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
•			•			•			•		

Specimens: 3 simulated samples.

Examinations: SARS-CoV-2 NAT.

Notes: Including variants. Scheme is not suitable for TMA methods (e.g. Hologic Aptima SARS-CoV-2 Assay). The samples contain hDNA.

POCT

5099 Tick-borne encephalitis virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		•			•			•			•

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: TBE IgG, IgM, total antibodies and post-analytical clinical interpretation.

Notes: For clinical laboratories and POCT sites.

POCT

EQA³

5665 Varicella-zoster virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 human single donor plasma or serum samples, 0.5 mL.

Examinations: Varicella zoster IgG, IgM, total antibodies and post-analytical clinical interpretation.

EQA³

5688 West Nile virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•		•		

Specimens: 2 human single donor plasma or serum samples, 0.5 mL.

Examinations: West Nile Virus IgG, IgM and total antibodies.

NEW

EQA schemes including Antimicrobial Susceptibility Testing

Bacteriology and mycology

5100	Blood culture
5190	Faecal culture (rounds 2 and 4)
5260	Fungal culture
5080	General Bacteriology 1
5081	General Bacteriology 2
5253	*Helicobacter pylori*, drug resistance, nucleic acid detection
5230	*Mycobacterium tuberculosis*, drug resistance, nucleic acid detection
5254	*Mycoplasma genitalium*, drug resistance, nucleic acid detection
5120	*Neisseria gonorrhoeae* (Gc), culture and susceptibility testing
5073	Surveillance for multidrug resistant bacteria, gramnegative rods
5071	Surveillance for multidrug resistant bacteria, MRSA
5072	Surveillance for multidrug resistant bacteria, VRE
5065	Urine culture, quantitative screening, identification and susceptibility

EQA schemes suitable for direct nucleic acid testing methods

Bacteriology

5241	*Bordetella pertussis/parapertussis*, nucleic acid detection
5612	*Chlamydia trachomatis* and *Neisseria gonorrhoeae*, nucleic acid detection
5201	*Clostridioides difficile*, nucleic acid detection
5191	Faecal bacterial pathogens multiplex, nucleic acid detection
5253	*Helicobacter pylori*, drug resistance, nucleic acid detection
5221	Mycobacterial nucleic acid detection
5230	*Mycobacterium tuberculosis*, drug resistance, nucleic acid detection
5254	*Mycoplasma genitalium*, drug resistance, nucleic acid detection
5599	*Streptococcus agalactiae (GBS)*, nucleic acid detection
5595	*Streptococcus pyogenes* (Group A), detection in pharyngeal sample
5071	Surveillance for multidrug resistant bacteria, MRSA
5072	Surveillance for multidrug resistant bacteria, VRE
5073	Surveillance for multidrug resistant bacteria, gramnegative rods

Multiplex

5191	Faecal bacterial pathogens multiplex, nucleic acid detection
5472	Faecal parasites multiplex, nucleic acid detection
5304	Gastrointestinal viral multiplex, nucleic acid detection
5303	Meningitis-encephalitis multiplex, nucleic acid detection
5300	Respiratory infections multiplex, nucleic acid detection
5302	Sexually transmitted diseases multiplex, nucleic acid detection
5305	Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Mycology

5261	Fungal infections, nucleic acid detection

Parasitology

5472	Faecal parasites multiplex, nucleic acid detection
5430	Malaria, antigen and nucleic acid detection
5473	*Trichomonas vaginalis*, detection

Virology

5651	CMV and EBV, nucleic acid detection, quantitative
5689	HCV RNA from capillary blood, POCT
5679	Hepatitis B virus, nucleic acid detection (DNA)
5678	Hepatitis C virus, nucleic acid detection (RNA)
5680	HIV-1, nucleic acid detection (RNA)
5556	HSV1&2/VZV/*Treponema pallidum*, nucleic acid detection
5086	Human papillomavirus, nucleic acid detection
5670	Influenza virus A+B and RS virus, nucleic acid detection
5562	Multiple Respiratory Virus, nucleic acid detection
5683	Mpox, nucleic acid detection
5675	Norovirus, nucleic acid detection
5676	SARS-CoV-2, nucleic acid detection

Multiplex

Multiplex EQA schemes are aimed to support laboratories to fulfill quality requirements of multiplex nucleic acid tests. All schemes include clinically relevant samples specially designed for multiplex nucleic acid testing. The multiplex schemes are annual programs and during the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5305 Bacterial vaginosis and vaginitis multiplex, nucleic acid detection (1)

NEW

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 3 simulated swab samples.

Examinations: *Atopobium vaginae*, BVAB2, *Gardnerella vaginalis*, *Lactobacillus spp.*, *Megasphaera-1*, *Candida albicans*, *Candida glabrata*, *Candida krusei*, *Candida glabrata/Candida krusei*, *Candida spp.*, *Trichomonas vaginalis*. Interpretation of bacterial vaginosis.

Notes: During the period of one calendar year, a comprehensive selection of listed microbes will be covered. The samples contain hDNA.

5100 Blood culture (incl. sepsis multiplex methods) (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•					•		•

Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and clinical strains.

Examinations: Culture, identification, antimicrobial susceptibility testing. Direct nucleic acid detection from positive blood culture bottles by multiplex methods is included in the scheme.

Notes: Fresh blood is needed but not included in the shipment.

5101 Blood culture, screening (incl. sepsis multiplex methods) (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•		•					•		•

Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation.

Examinations: Culture, preliminary identification using Gram staining and/or direct nucleic acid detection from positive blood culture bottles by multiplex methods. The scheme is also suitable for stem cell banks screening only for possible growth.

Notes: Fresh blood is needed but not included in the shipment.

5191 Faecal bacterial pathogens multiplex, nucleic acid detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
			•		•				•		•

Specimens: 3 samples. Either lyophilised mixtures of bacteria and/or simulated samples, 1 mL.

Examinations: Direct nucleic acid detection. Pathogens included are *Aeromonas*, *Campylobacter*, *C. difficile*, *E. coli* EHEC (stx1/stx2), *E. coli* EAEC, *E. coli* EIEC, *E. coli* EPEC, *E. coli* ETEC, *Plesiomonas*, *Salmonella*, *Shigella*, *Vibrio* and *Yersinia*.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5472 Faecal parasites multiplex, nucleic acid detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•			•			•	

Specimens: 3 lyophilised samples.

Examinations: Nucleic acid detection of *Cryptosporidium*, *Dientamoeba fragilis*, *Entamoeba histolytica* and *Giardia lamblia*.

5304 Gastrointestinal viral multiplex, nucleic acid detection (1)

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•			•

Specimens: 3 simulated samples, 1 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are: Adenovirus, Astrovirus, Norovirus GI and GII, Rotavirus, Sapovirus.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5303 Meningitis-encephalitis multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•		•	

Specimens: 3 simulated samples, 1 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are *Escherichia coli* K1, *Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae,* Cytomegalovirus (CMV), Enterovirus, Epstein-Barr virus (EBV), Herpes simplex virus 1 (HSV1), Herpes simplex virus 2 (HSV2), Human herpesvirus 6 (HHV6), Human parechovirus (HPeV), Varicella zoster virus (VZV) *Cryptococcus neoformans* and *Cryptococcus gattii.*

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5300 Respiratory infections multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
	•			•				•		•	

Specimens: 4 simulated samples, 1 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are adenovirus, bocavirus, *B. parapertussis, B. pertussis, C. pneumoniae,* coronavirus (OC43, 229E, NL63, HKU1), enterovirus, influenzavirus A/B, *L. pneumophila,* metapneumovirus, *M. pneumoniae,* parainfluenzavirus 1-4, rhinovirus, RSV A/B, SARS-CoV-2 and *S. pneumoniae.*

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. The samples contain hDNA.

5302 Sexually transmitted diseases multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
		•		•			•			•	

Specimens: 4 simulated swab/urine samples, 2 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are *C. trachomatis, M. genitalium, M. hominis, N. gonorrhoeae, T. vaginalis, U. parvum* and *U. urealyticum.*

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. The samples contain hDNA.

Pathology

Seven high quality schemes are available for pathology laboratories. With changing topics in the rounds, both routine and more advanced needs are covered. The challenges are realistic and include also less commonly encountered clinically relevant cases. In the cytology and histopathology schemes, virtual microscopy is used. With this technology, viewing of several fields of vision and levels of focus are enabled on a computer screen simulating analysis with an optical microscope. Please see the new scheme for HPV-related head and neck cancer under Others >> Oncology.

Pathology » Preanalytics

7806 Preanalytics and process in anatomic pathology (5)

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: 3-5 cases with preanalytical and process error(s).

Examinations: Participants are asked to find preanalytical or laboratory process error(s) in the cases.

Notes: The scheme is intended for all laboratory staff of pathology laboratories. Scheme is carried out online.

Pathology » Diagnostics

6542 Histopathology, virtual microscopy (5)

1	2	3	4	5	6	7	8	9	10	11	12
		•							•		

Topics: 1/2026 Thyroid gland, 2/2026 GI tract.

Specimens: Virtual images of at least 5 slides of miscellaneous tissue. Brief case histories and instructions are provided.

Examinations: Observations and diagnoses.

Notes: Topics may vary annually

6701 Gynaecological cytology (liquid based), virtual microscopy (5)

1	2	3	4	5	6	7	8	9	10	11	12
				•							

Specimens: Virtual images of at least 5 Papanicolaou stained slides of liquid based cytology (LBC) samples (ThinPrep). Diagnostics of cellular atypias in samples taken from gynaecological loci is assessed. Brief case histories and instructions are provided.

Examinations: Observations and diagnoses.

Notes: The virtual microscopy program does not work with Internet Explorer.

6700 Gynaecological cytology (smear), virtual microscopy (5)

1	2	3	4	5	6	7	8	9	10	11	12
		•									

Specimens: Virtual images of at least 5 Papanicolaou stained slides of conventional pap smear samples. The samples are selected from routine cytological material. Diagnostics of cellular atypias in samples taken from gynaecological loci is assessed. Brief case histories and instructions are provided.

Examinations: Observations and diagnoses.

Notes: The virtual microscopy program does not work with Internet Explorer.

6702 Non-gynaecological cytology, virtual microscopy (5)

1	2	3	4	5	6	7	8	9	10	11	12
									•		

Specimens: Virtual images of Papanicolaou stained slides of non-gynaecological cytosentrifuge (CCF) or smear preparations or May-Grünwald-Giemsa stained smears or imprint preparations. Images of at least 5 cases from representative loci. Brief case histories and instructions are provided.

Examinations: Observations and diagnoses.

Notes: The virtual microscopy program does not work with Internet Explorer.

Pathology » Technology

6543 Histological staining techniques (1)

1	2	3	4	5	6	7	8	9	10	11	12
				•					•		

Topics:
1/2026 HE + HE the participating laboratory's own slide.
2/2026 PAS, Elastin

Specimens: 1/2026 The participating laboratory will receive one unstained slide for HE staining. The second HE staining will be performed using the laboratory's own material according to instructions and sent for evaluation. 2/2026 Participants will receive two unstained slides.

6600 Immunohistochemical staining methods (1)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•		•	

Topics: 1/2026 CKPan, Ki67, SATB2. 2/2026 ER, PR, HER2. 3/2026 Chromogranin, Synaptophysin, INSM1

Specimens: Unstained paraffin embedded tissue from different tissue blocks or from one multiblock.

Examinations: Staining of the slides. A set of stained slides is returned to Aurevia for evaluation by an expert board.

Preanalytics

The preanalytical schemes provide laboratories and POCT sites with tools for extending quality assurance beyond the commonly assessed analytical phase. As a result of the improved analytical quality, most errors have been suggested to now occur in the preanalytical phase. Managing all phases of the total testing cycle is equally important to ensure patient safety.

8817 HIL-index (DEKS)

3

Three rounds per year.

Specimens: 2 samples, 1 mL each

Examinations: Organised in co-operation with DEKS. Participation in all rounds is required. Register orders before the end of December.

7806 Preanalytics and process in anatomic pathology

5

1	2	3	4	5	6	7	8	9	10	11	12
				•						•	

Specimens: 3-5 cases with preanalytical and process error(s).

Examinations: Participants are asked to find preanalytical or laboratory process error(s) in the cases.

Notes: The scheme is intended for all laboratory staff of pathology laboratories. The scheme is carried out online.

7800 Preanalytics, clinical chemistry

5

1	2	3	4	5	6	7	8	9	10	11	12
	•							•			

Specimens: 3 cases with preanalytical error(s).

Examinations: Participants are asked to find preanalytical error(s) in the cases.

Notes: The scheme is intended for personnel using POCT tests and devices. The scheme is carried out online.

7802 Preanalytics, microbiology

5

1	2	3	4	5	6	7	8	9	10	11	12
			•						•		

Specimens: 3 cases with preanalytical error(s).

Examinations: Participants are asked to find preanalytical error(s) in the cases.

Notes: The scheme is intended for all laboratory staff of clinical microbiology laboratories. The scheme is carried out online.

7807 Preanalytics, Pneumatic Sample Transport

3

1	2	3	4	5	6	7	8	9	10	11	12
								•			

Specimens: Two surrogate blood vials (i.e. measurement devices for recording 3-axis acceleration during pneumatic tube system transport (PTS).

Examinations: Vials are sent through the PTS as regular blood samples, no laboratory analysis is performed. Rejection probability of LDH, ASAT and K will be calculated using the cumulative vibration level, laboratory defined analyte-specific hemolysis cutoffs, and a hemolysis model.

Notes: Vials are sent to the participating laboratories during September-October. Laboratories are asked to perform the recordings within one week upon receiving the vials and to return the vials using a courier (shipping costs not included). It is possible to measure 3 different lines from the same PTS manufacturer.

POCT

7804 Preanalytics, POCT in chemistry

5

1	2	3	4	5	6	7	8	9	10	11	12
									•		

Specimens: 3 cases with preanalytical error(s).

Examinations: Participants are asked to find preanalytical error(s) in the cases.

Notes: The scheme is intended for personnel using POCT tests and devices. The scheme is carried out online.

POCT

7801 Preanalytics, urine and blood sample collection

5

1	2	3	4	5	6	7	8	9	10	11	12
		•									

Specimens: 3 cases with preanalytical error(s).

Examinations: Participants are asked to find preanalytical error(s) in the cases.

Notes: The scheme is intended for personnel performing blood and urine sample collection. Scheme is carried out online.

Others

Others » Andrology

6400 Semen analysis (3)

1 2 3 4 5 6 7 8 9 10 11 12
- - - - - - - - - • - -

Specimens: 2-3 digital image series to assess morphology, 2-3 videos to assess sperm concentration and motility, 1 image series to assess sperm vitality.

Examinations: Sperm concentration, morphology, motility, vitality.

Notes: The scheme is carried out online.

Others » Clinical physiology

7130 ECG, interpretation (1)

1 2 3 4 5 6 7 8 9 10 11 12
- - • - - - - • - - - -

EQA³

Specimens: 3 digital ECG registrations (images).

Examinations: Technical quality and findings.

Notes: The scheme is designed for nurses and general practitioners as well as for personnel in POCT units. Participants are evaluated on their responses on technical quality, findings or both if given.

Others » Genetics

8850 DNA sequencing (EQUALIS) (1)

1 2 3 4 5 6 7 8 9 10 11 12
One round per year.

Specimens: Two samples (amplicons) and two primer pairs for a total of 4 sequence reactions are distributed to the participants.

Examinations: Both ability to identify the sequence and report according to HGVS nomenclature are assessed.

Notes: Organised in co-operation with Equalis. Participation in all rounds is required. Register orders before the end of December.

3865 DNA single nucleotide variation (EQUALIS) (1)

1 2 3 4 5 6 7 8 9 10 11 12
Two rounds per year.

Specimens: Whole blood or extracted DNA. Blank samples (water) are sometimes included.

Examinations: DNA-Apolipoprotein E genotype, DNA-Factor 2 (F2) g.20210G>A, DNA-Factor 5 (F5) c.1691G>A, DNA-Hemochromatosis (HFE) c.187C>G; c.845G>A, DNA-Lactase gene (LCT) g.13910C>T, DNA-Methylene tetrahydropholate reductase (MTHFR) c.677C>T; c.1298A>Cx.

Notes: Organised in co-operation with Equalis. Participation in all rounds is required. Register orders before the end of December.

Others » Laboratory instruments

8814 ELISA reader photometry control (DEKS) (1)

1 2 3 4 5 6 7 8 9 10 11 12
One round per year.

Specimens: An ELISA-plate with built-in gray glass filters.

Examinations: Control for the absorbance scale in ELISA reader.

Notes: Absorbance traceable to NIST Control of the absorbance scale of ELISA readers. Organised in co-operation with DEKS. Register orders before the end of December.

8205 Pipette control (5)

1 2 3 4 5 6 7 8 9 10 11 12
- • - - - - - • - - - -

Specimens: 2 liquid samples.

Examinations: 100 - 1000 µL of the liquid samples shall be weighed by the participant, the result is reported in mg with a precision of two decimal places.

Notes: Up to 5 single-channel pipettes can be controlled. A calibrated laboratory scale with 0.01 mg resolution is required. This EQA scheme does not replace standardized pipette calibration, it does not fulfill the accreditation requirements for pipette calibration.

Others » Oncology

NEW

6800 HPV-related head and neck cancer control: HPV-NAT + IHC p16 (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 2 cell-derived samples each including one paraffin section on a slide for IHC p16 and paraffin scrolls in a vial for NAT.

Examinations: Slide: IHC p16 staining and interpretation.
Scrolls: HPV nucleic acid detection.

Notes: p16 IHC staining to be performed on slides and HPV NAT to be perfomed on scrolls in vials.

NEW

6802 HPV-related head and neck cancer control: IHC p16 (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 2 cell-derived samples each including one paraffin section on a slide for IHC p16.

Examinations: Slide: IHC p16 staining and interpretation.

Notes: p16 IHC staining to be performed on slides.

NEW

6801 HPV-related head and neck cancer control: HPV-NAT (3)

1	2	3	4	5	6	7	8	9	10	11	12
		•						•			

Specimens: 2 cell-derived samples each including paraffin scrolls in a vial for NAT.

Examinations: Scrolls: HPV nucleic acid detection.

Notes: HPV NAT to be performed on paraffin scrolls. Please see full product 6800 in the Oncology section.

External quality assessment for extra-analytical phases

PREANALYTICAL EQA | ANALYTICAL EQA | POSTANALYTICAL EQA

We have two advanced external quality assessment programs for extra-analytical phases of clinical laboratory investigation process. Preanalytical EQA programs are independent schemes for the evaluation of preanalytical phase and Integrated EQA programs includes pre- and/or postanalytical evaluation together with traditional EQA samples.

Pre- and postanalytical EQA programs

Preanalytical EQA programs

8817	HIL-index (DEKS)
7800	Preanalytics, clinical chemistry
7802	Preanalytics, microbiology
7806	Preanalytics and process in anatomic pathology
7807	Preanalytics, Pneumatic sample transport
7804	Preanalytics, POCT in chemistry
7801	Preanalytics, urine and blood sample collection

Integrated EQA programs

Clinical chemistry

2610	Acid-base status and electrolytes
2570, 2580, 2590	Glucose meters
2114	Haemoglobin, 1-level, POCT
2300, 2300S	Hormones A: Basic analytes of hormone and immunochemistry
2301, 2301S	Hormones B: Steroid and peptide hormones
2200	Lipids and lipoproteins
2240	Proteins, electrophoresis
2050	General clinical chemistry, 2-level sera (serum B and C
3100, 3102	Urine strip test A
3130	Urine strip test B
2480	Vitamin A, E and D metabolites

Clinical physiology

7130	ECG, interpretation

Haematology

4480	Column agglutination methods: grading of reactions and patient cases

Immunology

5935	ANCA and GbmAb
5900	Antinuclear antibodies
5940	Coeliac disease, antibodies
5250	Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis*

Microbiology

5950	*Bordetella pertussis,* antibodies
5960	*Borrelia burgdorferi,* antibodies, European origin
5620	*Chlamydia pneumoniae*, antibodies
5650	Cytomegalovirus, antibodies
5635	Dengue virus, antibodies and antigen detection
5641	EBV mononucleosis, specific antibodies
5080	General Bacteriology 1 (aerobes and anaerobes)
5081	General Bacteriology 2 (aerobes)
5860	Helicobacter pylori, antibodies
5092	Hepatitis A, antibodies
5094-5096	Hepatitis B and C, serology
5682	Hepatitis E, antibodies
5091	HIV, antibodies and antigen detection
5089	Human T-cell lymphotropic virus, antibodies
5668	Measles virus, antibodies
5669	Mumps virus, antibodies
5980	*Mycoplasma pneumoniae,* antibodies
5660	Parvovirus B19, antibodies
5560	Puumala virus, antibodies
5667	Rubella virus, antibodies
5880	Syphilis serology
5099	Tick-borne encephalitis virus, antibodies
5420	Toxoplasma, antibodies
5060	Urine culture, quantitative screening
5065	Urine culture, quantitative screening
5665	Varicella-zoster virus, antibodies

Alphabetical scheme directory

Alphabetical scheme directory

Alphabetical scheme directory

LABQUALITY DAYS

50th Anniversary

5-6 February 2026 | Helsinki, Finland

International Congress on Quality in Laboratory Medicine & Health Technology

Labquality Days is one of the largest international congresses in Northern Europe focusing on quality in **laboratory medicine and health technology**. 2026 marks the 50th anniversary of the congress!

The inspiring atmosphere of the scientific congress gathers medical laboratory and health technology professionals together to exchange ideas and meet colleagues in Finland annually.

In addition to the extensive scientific program, the congress includes an exhibition of companies in the field of clinical laboratory, IT and health technology, and an **ePoster exhibition** where you can share your research and project results.

Join us in this special anniversary year to hear the latest developments in laboratory medicine and health technology, and spend a couple of days in beautiful winter Helsinki!

Under the auspices of:

EFLM
EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

ifcc
International Federation of Clinical Chemistry and Laboratory Medicine

Labquality EQAS

info@labquality.com | +358 9 8566 8200
Kumpulantie 15, 00520 Helsinki, Finland